AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026. CEO Thomas K. Equels will present a corporate overview and business outlook with emphasis on AIM's strategic focus on pancreatic cancer.
Presentation details: Wednesday, February 11, 2026 at 1:40 PM EST; registration and current corporate presentation on Ampligen breakthroughs are available.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AIM declined 7.32%, reflecting a notable negative market reaction. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $311K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 19.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AIM rose 16.59% while key biotech peers (TNFA, BCLI, HCWB, NCNA, PMCB) showed same-day declines between about -1.8% and -10.3%, pointing to a stock-specific move rather than a sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Clinical trial update | Positive | +16.6% | Phase 2 interim data for Ampligen plus Imfinzi in pancreatic cancer. |
| Jan 27 | Rights offering terms | Negative | +0.0% | Amended dates and terms for a planned $12.0M rights offering. |
| Jan 23 | Rights offering launch | Negative | -5.2% | Announcement of rights offering units with preferred stock and warrants. |
| Dec 30 | Stock dividend | Neutral | -4.4% | One-for-1,000 stock dividend and related allocation details. |
| Dec 10 | CEO communication | Neutral | -2.7% | CEO Corner video discussing unmet pancreatic cancer need and Ampligen. |
Recent AIM moves often align with news tone: positive clinical and financing updates saw matching price direction, while communication-focused items like stock dividends and CEO media have sometimes met with negative reactions.
Over the last few months, AIM has combined capital-raising steps with oncology progress. A Feb 5, 2026 Phase 2 interim update in pancreatic cancer coincided with a 16.59% rise. January rights-offering announcements targeted up to $12.0 million and produced mixed reactions. A December stock dividend and a CEO Corner segment on Ampligen drew modest share price declines. Today’s webinar notice continues the pattern of investor outreach around the pancreatic cancer program.
Regulatory & Risk Context
An effective Form S-3/A shelf dated 2025-06-27 authorizes issuance of up to $100 million across multiple security types, giving AIM flexibility to raise capital in tranches and creating ongoing dilution risk as offerings, such as the 424B5 usage on 2025-07-30, are launched.
Market Pulse Summary
The stock moved -7.3% in the session following this news. A negative reaction despite essentially informational webinar news would have been consistent with prior instances where communication-focused updates drew selling pressure. In that scenario, traders might have focused more on dilution overhang from the effective $100 million shelf and recent offerings than on incremental visibility from the presentation. Past divergence around dividends and media outreach suggests sentiment can turn quickly when no new clinical or financial metrics accompany announcements.
Key Terms
pancreatic cancer medical
AI-generated analysis. Not financial advice.
Live video webcast on Wednesday, February 11th at 1:40 PM EST
OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.
As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM’s strategic emphasis on pancreatic cancer.
Details of the presentation are as follows:
Date and Time: Wednesday, February 11, 2026 at 1:40 PM EST
Presenter: Thomas K. Equels, MS JD, Chief Executive Officer
Registration Link: Here
See AIM's current corporate presentation: Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer: Corporate Presentation – February 2026
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
When will AIM ImmunoTech (AIM) present at the Webull Corporate Connect Webinar Series?
Who will present for AIM (AIM) at the February 11, 2026 webinar and what will they cover?
How can investors register to attend AIM ImmunoTech's (AIM) virtual presentation on February 11, 2026?
Will AIM (AIM) provide materials or a corporate presentation during the Webull webinar?
Is the AIM ImmunoTech (AIM) presentation at Webull expected to discuss clinical or financial results?
